MONTE ROSA THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.33 USD | -2.20% |
|
-8.89% | -5.66% |
| Mar. 14 | Monte Rosa Therapeutics Q4 Net Loss Narrows; Shares Decline | MT |
| Mar. 14 | Monte Rosa Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
Financials (USD)
| Sales 2024 * | 6.18M | Sales 2025 * | 5.93M | Capitalization | 268M |
|---|---|---|---|---|---|
| Net income 2024 * | -144M | Net income 2025 * | -169M | EV / Sales 2024 * | 24.9 x |
| Net cash position 2024 * | 114M | Net cash position 2025 * | 174M | EV / Sales 2025 * | 16 x |
| P/E ratio 2024 * |
-2.24
x | P/E ratio 2025 * |
-2.36
x | Employees | 133 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.11% |
More Fundamentals
* Assessed data
More news
Latest transcript on Monte Rosa Therapeutics, Inc.
More recommendations
More press releases
| 1 day | -2.20% | ||
| 1 week | -8.89% | ||
| Current month | -24.40% | ||
| 1 month | -19.12% | ||
| 3 months | -1.84% | ||
| 6 months | +113.20% | ||
| Current year | -5.66% |
1 week
5.11
6.05
1 month
5.118.22
Current year
4.198.84
1 year
2.448.84
3 years
2.4445.56
5 years
2.4445.56
10 years
2.4445.56
| Managers | Title | Age | Since |
|---|---|---|---|
Markus Warmuth
CEO | Chief Executive Officer | 53 | 19-12-31 |
| Chief Operating Officer | - | 21-02-28 | |
Filip Janku
CTO | Chief Tech/Sci/R&D Officer | 50 | 21-05-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Andrew Schiff
BRD | Director/Board Member | 58 | 20-08-31 |
Christine Siu
BRD | Director/Board Member | 47 | 20-11-30 |
Chandra Paul Leo
BRD | Director/Board Member | 55 | 20-08-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.02% | 0 M€ | 0.00% | - | |
| 0.02% | 0 M€ | 0.00% | - | |
| 0.00% | 9 M€ | +6.26% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 5.33 | -2.20% | 87,737 |
| 24-04-25 | 5.45 | -0.37% | 134,428 |
| 24-04-24 | 5.47 | -1.26% | 82,888 |
| 24-04-23 | 5.54 | +0.73% | 76,395 |
| 24-04-22 | 5.5 | -5.98% | 118,915 |
Delayed Quote Nasdaq, April 26, 2024 at 04:00 pm EDT
More quotes
Monte Rosa Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a portfolio of novel and molecular glue degraders (MGDs) for patients living with serious diseases in the areas of oncology and autoimmune, and more. MGDs are small molecule drugs that employ the bodyâs natural protein destruction mechanisms to selectively degrade therapeutically relevant proteins. It has developed a degradation platform, called Quantitative and Engineered Elimination of Neosubstrates (QuEEN) to enable its target centric MGD discovery and development approach and its rational design of MGD product candidates. Its product candidate, MRT-2359, is an orally bioavailable MGD targeting the translation termination factor protein GSPT1. MRT-2359 is in clinical development for potential use in MYC-driven tumors, including metastatic non-small cell lung cancer, small cell lung cancer and neuroendocrine tumors. Its other product candidates include MRT-6160 and MRT-8102.
Calendar
2024-05-08
- Q1 2024 Earnings Release (Projected)
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
5.33
USD
Average target price
15.71
USD
Spread / Average Target
+194.83%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -5.66% | 267M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- GLUE Stock
